Silence Therapeutics Stock Forward View
| SLN Stock | USD 6.95 -0.03 -0.43% |
Momentum
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter -0.51 | EPS Estimate Current Year -0.80 | EPS Estimate Next Year -0.72 | Wall Street Target Price 32.8 | EPS Estimate Current Quarter -0.49 |
This section provides headline-driven context for Silence Therapeutics PLC alongside peer activity. The sentiment layer reflects Silence Therapeutics' options activity and short interest context.
Access complete reports via Days Sales Outstanding and Ptb Ratio.
Silence Therapeutics Implied Volatility | 2.76 |
When Silence Therapeutics' implied volatility is unusually high relative to its historical average, options premiums are inflated. Sophisticated investors may choose to sell options in this environment to collect elevated premium income.
The Naive Prediction forecasted value of Silence Therapeutics PLC on the next trading day is expected to be 6.98 with a mean absolute deviation of 0.17 and the sum of the absolute errors of 10.10.Silence Therapeutics after-hype prediction price | $ 6.92 |
The sentiment panel provides context that can be compared with forecasting models and technical indicators.
Historical Fundamental Analysis of Silence Therapeutics can be used to cross-verify projections for Silence Therapeutics. The historical series provides projection context.Open Interest Context: Silence 2026-04-17 Options
Open interest represents the number of active Silence Therapeutics option contracts and offers a participation signal.
Silence Therapeutics Additional Predictive Modules
Most predictive techniques to examine Silence price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Silence using various technical indicators. When you analyze Silence charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Silence Therapeutics Cash Forecast
Accurate cash forecasting for Silence Therapeutics requires identifying the key drivers embedded in Silence Therapeutics' financial statements - revenue growth rates, margin trends, and working capital efficiency - and modeling how they evolve over time.
Cash | First Reported 2003-06-30 | Previous Quarter 82 M | Current Value 11.3 M | Quarterly Volatility 31.4 M |
Macro event markers
Silence Therapeutics Naive Prediction Price Forecast For the 13th of March 2026
Given 90 days horizon, the Naive Prediction forecasted value of Silence Therapeutics PLC on the next trading day is expected to be 6.98 with a mean absolute deviation of 0.17 , mean absolute percentage error of 0.05 , and the sum of the absolute errors of 10.10 .Please note that although there have been many attempts to predict Silence Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Silence Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Silence Therapeutics Stock Forecast Pattern
| Backtest Silence Therapeutics | Silence Therapeutics Price Prediction | Research Analysis |
Silence Therapeutics Forecasted Value
This next-day forecast for Silence Therapeutics PLC uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Silence Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Silence Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 115.0124 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.1655 |
| MAPE | Mean absolute percentage error | 0.0305 |
| SAE | Sum of the absolute errors | 10.0983 |
The mean reversion effect in Silence Therapeutics is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Silence Therapeutics' price dislocation is essential before acting.
Silence Therapeutics After-Hype Price Density Analysis
The probability distribution for Silence Therapeutics' predicted price encodes the full spectrum of outcomes, weighted by their estimated likelihood. Investors should compare this range against their personal risk tolerance before committing to Silence Therapeutics positions.
Next price density |
| Expected price to next headline |
Silence Therapeutics Estimiated After-Hype Price Volatility
The news prediction model for Silence Therapeutics analyzes the correlation between Silence Therapeutics' historical headline events and same-day or next-day price movements. Silence Therapeutics' after-hype downside and upside margins for the prediction period are 2.13 and 11.71, respectively. Predictive accuracy varies significantly across different news categories and market regimes for Silence Therapeutics.
Current Value
The after-hype framework applied to Silence Therapeutics PLC assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Silence Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Silence Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Silence Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Silence Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.27 | 4.79 | 0.03 | 0.03 | 7 Events | 7 Events | In 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
6.95 | 6.92 | 0.43 |
|
Silence Therapeutics Hype Timeline
On the 12th of March 2026 Silence Therapeutics PLC is traded for 6.95. The company has historical hype elasticity of -0.03, and average elasticity to hype of competition of 0.03. Silence is expected to decline in value after the next headline, with the price expected to drop to 6.92. The average volatility of media hype impact on the company price is over 100%. The price depreciation on the next news is expected to be -0.43%, whereas the daily expected return is at this time at 0.27%. The volatility of related hype on Silence Therapeutics is about 5095.74%, with the expected price after the next announcement by competition of 6.98. About 24.0% of the company outstanding shares are owned by corporate insiders. The book value of Silence Therapeutics was at this time reported as 1.32. The company recorded a loss per share of 1.35. Silence Therapeutics PLC had not issued any dividends in recent years. Considering the 90-day investment horizon the next expected press release will be in 7 days. Historical Fundamental Analysis of Silence Therapeutics can be used to cross-verify projections for Silence Therapeutics. The historical series provides projection context.Silence Therapeutics Related Hype Analysis
Sector-wide news events often affect Silence Therapeutics before the fundamental impact on Silence Therapeutics' own business becomes clear. Peer hype analysis helps investors distinguish between sector-level sentiment shifts and Silence Therapeutics-specific developments.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CTNM | Contineum Therapeutics Class | 0.37 | 7 per month | 3.80 | 0.12 | 8.89 | -7.07 | 26.95 | |
| AMRN | Amarin PLC | 0.20 | 8 per month | 3.18 | 0.02 | 6.11 | -4.37 | 26.36 | |
| KYTX | Kyverna Therapeutics Common | -0.08 | 10 per month | 7.48 | 0.06 | 10.60 | -8.52 | 55.75 | |
| ALDX | Aldeyra | -0.18 | 9 per month | 4.76 | 0.03 | 8.64 | -9.21 | 43.66 | |
| CAPR | Capricor Therapeutics | -0.17 | 8 per month | 4.53 | 0.06 | 9.04 | -6.69 | 18.57 | |
| LXEO | Lexeo Therapeutics Common | -0.31 | 6 per month | 0.00 | -0.07 | 6.22 | -6.37 | 34.26 | |
| LYEL | Lyell Immunopharma | 0.83 | 7 per month | 5.05 | 0.02 | 7.13 | -8.14 | 24.69 | |
| MREO | Mereo BioPharma Group | 0.00 | 12 per month | 0.00 | -0.02 | 16.33 | -9.52 | 101.95 | |
| ANRO | Alto Neuroscience | 0.11 | 8 per month | 4.09 | 0.19 | 10.39 | -7.29 | 23.67 | |
| ACIU | AC Immune | 0.17 | 6 per month | 4.20 | 0.04 | 7.29 | -8.38 | 26.05 |
Other Forecasting Options for Silence Therapeutics
For both new and experienced investors in Silence, the ability to analyze Silence Therapeutics' price movement is a fundamental investment skill. Price chart noise in Silence Stock can create false signals and mislead investment decisions.Silence Therapeutics Related Equities
The following equities are related to Silence Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Silence Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Silence Therapeutics Market Strength Events
Tracking market strength indicators for Silence Therapeutics helps investors understand the momentum dynamics of the stock in real time. These signals support informed decisions about when to enter or exit positions in Silence Therapeutics PLC for maximum return potential.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 6.95 | |||
| Day Typical Price | 6.95 | |||
| Price Action Indicator | -0.01 | |||
| Period Momentum Indicator | -0.03 | |||
| Relative Strength Index | 63.54 |
Silence Therapeutics Risk Indicators
Properly assessing Silence Therapeutics' risk indicators is a prerequisite for building reliable price forecasts. Identifying and quantifying the risks associated with Silence Therapeutics' allows investors to make better-informed decisions about accepting or hedging their exposure.
| Mean Deviation | 3.48 | |||
| Semi Deviation | 4.21 | |||
| Standard Deviation | 4.81 | |||
| Variance | 23.11 | |||
| Downside Variance | 19.45 | |||
| Semi Variance | 17.7 | |||
| Expected Short fall | -3.91 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Silence Therapeutics
Coverage intensity for Silence Therapeutics PLC matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Silence Therapeutics Short Properties
Short sentiment tied to Silence Therapeutics PLC matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 47.2 M | |
| Cash And Short Term Investments | 85.1 M |
More Resources for Silence Stock Analysis
A comprehensive view of Silence Therapeutics PLC starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Silence Therapeutics PLC Stock. Key reports that frame Silence Therapeutics PLC Stock are listed below:Historical Fundamental Analysis of Silence Therapeutics can be used to cross-verify projections for Silence Therapeutics. The historical series provides projection context. Analysis related to Silence Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Earnings Share -1.35 | Revenue Per Share | Quarterly Revenue Growth -1.00 | Return On Assets | Return On Equity |
Silence Therapeutics PLC market price can diverge from book value, the accounting figure shown on Silence balance sheet. Silence Therapeutics' market capitalization is 329.69 M. With a P/B ratio of 3.99, the market values Silence Therapeutics well above its book equity. Enterprise value stands at 181.39 M. Intrinsic value is an analytical estimate of Silence Therapeutics' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
It is useful to distinguish Silence Therapeutics' value from its trading price, which are computed with different methods. For Silence Therapeutics, key inputs include a P/B ratio of 3.99, ROE of -90.27%, and revenue of 559 K. By contrast, market price reflects the level where buyers and sellers transact.